Mark Rawson, DPM in Astoria, OR - Medicare Podiatry Provider

Mark Rawson, DPM is a medicare enrolled "Podiatrist" provider in Astoria, Oregon. He went to California School Of Podiatric Medicine and graduated in 1993 and has 31 years of diverse experience with area of expertise as Podiatry. He is a member of the group practice Columbia Lutheran Charities and his current practice location is 2265 Exchange St, Astoria, Oregon. You can reach out to his office (for appointments etc.) via phone at (503) 338-4075.

Mark Rawson is licensed to practice in Oregon (license number DP195825) and he also participates in the medicare program. He accepts medicare assignments (which means he accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance) and his NPI Number is 1841261625.

Contact Information

	Mark Rawson, DPM
	2265 Exchange St, Astoria, OR 97103-3331
	(503) 338-4075
	(503) 338-4076

Healthcare Provider's Profile

Full Name	Mark Rawson
Gender	Male
Speciality	Podiatry
Experience	31 Years
Location	2265 Exchange St, Astoria, Oregon
Accepts Medicare Assignments	Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance.

Medical Education and Training:

Mark Rawson attended and graduated from California School Of Podiatric Medicine in 1993

NPI Data:

NPI Number: 1841261625
Provider Enumeration Date: 01/30/2006
Last Update Date: 02/23/2022

Medicare PECOS Information:

PECOS PAC ID: 1557415528
Enrollment ID: I20191121000597

Medical Identifiers

Medical identifiers for Mark Rawson such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1841261625	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
213E00000X	Podiatrist	DP195825 (Oregon)	Primary

Medical Facilities Affiliation

Facility Name	Location	Facility Type
Columbia Memorial Hospital	Astoria, OR	Hospital

Group Practice Association

Group Practice Name	Group PECOS PAC ID	No. of Members
Columbia Lutheran Charities	5294643359	78

News Archive

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

Describing PEPFAR as "a targeted approach on a large-scale and with accountability for results," U.S. Global AIDS Coordinator Ambassador Eric Goosby on Tuesday said the program has done more than fight HIV/AIDS, having had a "broader transformational impact ... on the health sector" in many countries, VOA News reports.

UCLan and AUC launch new medical program to help address global doctor shortage

As countries around the globe experience a worsening shortage of doctors, a new partnership based in the United Kingdom offers hope in an innovative approach.

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

Scientists from The Scripps Research Institute have provided an answer to the 40-year-old mystery of how certain genetic mutations lead to Type 1 diabetes. This new molecular understanding could lead to novel therapies for Type 1 diabetes and other autoimmune diseases.

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

EraGen Biosciences, a rapidly growing molecular diagnostics company and Bayer HealthCare LLC, Diagnostics Division, announced today that EraGen has licensed its patented MultiCode-PLx® System to Bayer HealthCare in an exclusive worldwide agreement for Cystic Fibrosis.

Medicare Reassignments

Some practitioners may not bill the customers directly but medicare billing happens through clinics / group practice / hospitals where the provider works. Medicare reassignment of benefits is a mechanism by which practitioners allow third parties to bill and receive payment for medicare services performed by them. Mark Rawson allows following entities to bill medicare on his behalf.

Provider Name	Columbia Lutheran Charities
Provider Type	Part A Provider - Critical Access Hospital
Provider Identifiers	NPI Number: 1134146939 PECOS PAC ID: 5294643359 Enrollment ID: O20021217000028

News Archive

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

As countries around the globe experience a worsening shortage of doctors, a new partnership based in the United Kingdom offers hope in an innovative approach.

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

As countries around the globe experience a worsening shortage of doctors, a new partnership based in the United Kingdom offers hope in an innovative approach.

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Mark Rawson is enrolled with medicare and thus, if eligible, can prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Mark Rawson, DPM 2111 Exchange St, Astoria, OR 97103-3329 Ph: (503) 325-4321	Mark Rawson, DPM 2265 Exchange St, Astoria, OR 97103-3331 Ph: (503) 338-4075

News Archive

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

The U.S. Food and Drug Administration today approved a new use of Gleevec (imatinib) to treat children newly diagnosed with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL).

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

As countries around the globe experience a worsening shortage of doctors, a new partnership based in the United Kingdom offers hope in an innovative approach.

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Podiatrist in Astoria, OR

Michael A. Murdock, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2265 Exchange St, Astoria, OR 97103 Phone: 503-338-4075 Fax: 503-338-4076
Mark Owen Ellis, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 582 22nd Street, Astoria, OR 97103 Phone: 503-325-0045 Fax: 503-325-3242
Rivershore Foot And Ankle Clinic Inc. Podiatrist Medicare: Medicare Enrolled Practice Location: 2120 Exchange St Ste 110, Astoria, OR 97103 Phone: 503-325-5655 Fax: 503-325-1317
Dr. Nancy Ray, MD Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 2120 Exchange St Ste 110, Astoria, OR 97103 Phone: 503-325-5655
Rivershore Foot & Ankle Clinic, Inc Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 2120 Exchange St Ste 110, Astoria, OR 97103 Phone: 503-325-5655

Mark Rawson, DPM - Medicare Podiatrist in Astoria, OR

Contact Information

Healthcare Provider's Profile

Medical Identifiers

Medical Taxonomies and Licenses

Medical Facilities Affiliation

Group Practice Association

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Medicare Reassignments

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Medicare Part D Prescriber Enrollment

Mailing Address and Practice Location

Novartis receives FDA approval for Ph+ acute lymphoblastic leukemia

PEPFAR strengthens AIDS programs, broader health care systems, Goosby says

UCLan and AUC launch new medical program to help address global doctor shortage

Certain genetic mutations lead to Type 1 diabetes: The Scripps Research Institute

EraGen Biosciences and Bayer announce agreements for new cystic fibrosis (CF) assay

Podiatrist in Astoria, OR